Using blood methylation markers to detect recurrence and monitor minimal residual disease in lung cancer
Official title: Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
Run by Beijing Haidian Hospital · NCT07257458 · Data updated 2026-11-12
This project will test whether tracking two blood DNA methylation markers (SHOX2 and PTGER4) can detect minimal residual disease and predict recurrence in patients after non-small cell lung cancer surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Beijing Haidian Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 2, 2025 |
| Main results expected | June 30, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT07257458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–85 with histologically or clinically confirmed NSCLC who are eligible for surgical resection, have ECOG ≤2, and can comply with serial blood draws and follow-up are ideal candidates.
✕Probably not a fit
Patients with other active malignancies, severe comorbidities that prevent surgery, pregnant or lactating individuals, or those unlikely to complete follow-up or provide adequate samples may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study followed patients with stage I–IV non‑small cell lung cancer who underwent surgical resection and collected peripheral blood before surgery and at multiple timepoints up to 24 months postoperatively to measure SHOX2 and PTGER4 methylation in circulating tumor DNA. Serial methylation levels were compared with conventional tumor markers and imaging to see whether rising methylation signals precede radiographic recurrence. The aim was to identify high‑risk patients who might benefit from personalized adjuvant therapy and to reduce overtreatment or undertreatment. Statistical analyses examined correlations between methylation dynamics and clinical recurrence outcomes.
Why it matters
Potential benefit: If successful, this approach could detect recurrence earlier than imaging and help tailor adjuvant therapy to avoid over- or undertreatment.
How similar studies have gone: Previous research has shown that methylation markers including SHOX2 and PTGER4 can detect lung cancer and show promise for MRD monitoring, but large prospective validation for guiding adjuvant therapy remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with non-small cell lung cancer (NSCLC) by histopathology/clinical diagnosis. * Age 18-85 years old. * Lung cancer patients who are determined by clinicians to be eligible for surgical treatment. * ECOG score ≤ 2, with an expected survival period of ≥ 6 months, and having signed the informed consent form. * The subjects should have clear case information, including age, gender, and clinical diagnosis, etc. Exclusion Criteria: * Patients with a history of other malignant tumors or autoimmune diseases. * Those with severe heart, lung or vascular diseases that make them unable to tolerate surgery. * Pregnant or lactating women. * Patients who may be unable to complete follow-up during the study, as well as other factors that the researcher deems inappropriate for participation in the study. * Incomplete clinical or follow-up information.
Where it's running
-
Beijing Haidian Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Yuqing Huang — Beijing Haidian Hospital
- Study coordinator: Yuqing Huang, Ph.D
- Email: huangyuqing555@qq.com
- Phone: +86 13371735630
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.